565 related articles for article (PubMed ID: 30558790)
1. Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.
Huang R; Duan X; Liu X; Cao H; Wang Y; Fan J; Wang B
Biochem Biophys Res Commun; 2019 Jan; 508(4):1252-1258. PubMed ID: 30558790
[TBL] [Abstract][Full Text] [Related]
2. Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease.
Ding J; Li M; Wan X; Jin X; Chen S; Yu C; Li Y
Sci Rep; 2015 Sep; 5():13729. PubMed ID: 26330104
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway.
Chen J; Chen J; Fu H; Li Y; Wang L; Luo S; Lu H
Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E710-E722. PubMed ID: 31430204
[TBL] [Abstract][Full Text] [Related]
4. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease.
Liu J; Tang T; Wang GD; Liu B
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31064820
[No Abstract] [Full Text] [Related]
5. MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease.
Xu M; Zheng XM; Jiang F; Qiu WQ
J Cell Biochem; 2018 Jul; 119(7):5864-5874. PubMed ID: 29575055
[TBL] [Abstract][Full Text] [Related]
6. circRNA_0046366 inhibits hepatocellular steatosis by normalization of PPAR signaling.
Guo XY; Sun F; Chen JN; Wang YQ; Pan Q; Fan JG
World J Gastroenterol; 2018 Jan; 24(3):323-337. PubMed ID: 29391755
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
[TBL] [Abstract][Full Text] [Related]
8. Decreased MiR-155 Level in the Peripheral Blood of Non-Alcoholic Fatty Liver Disease Patients may Serve as a Biomarker and may Influence LXR Activity.
Wang L; Zhang N; Wang Z; Ai DM; Cao ZY; Pan HP
Cell Physiol Biochem; 2016; 39(6):2239-2248. PubMed ID: 27832630
[TBL] [Abstract][Full Text] [Related]
9. Aberrant miR199a-5p/caveolin1/PPARα axis in hepatic steatosis.
Li B; Zhang Z; Zhang H; Quan K; Lu Y; Cai D; Ning G
J Mol Endocrinol; 2014 Dec; 53(3):393-403. PubMed ID: 25312970
[TBL] [Abstract][Full Text] [Related]
10. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
Long JK; Dai W; Zheng YW; Zhao SP
Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
[TBL] [Abstract][Full Text] [Related]
12. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H
Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599
[TBL] [Abstract][Full Text] [Related]
13. FMO1 Promotes Nonalcoholic Fatty Liver Disease Progression by Regulating PPARα Activation and Inducing Ferroptosis.
Zou L; Shi Q; Li Y; Yuan Z; Peng L; Lu J; Zhu H; Ma J
Discov Med; 2023 Aug; 35(177):612-622. PubMed ID: 37553313
[TBL] [Abstract][Full Text] [Related]
14. Pdcd4 promotes lipid deposition by attenuating PPARα-mediated fatty acid oxidation in hepatocytes.
Du X; Osoro EK; Chen Q; Yan X; Gao D; Wu L; Ren J; Feng L; Wu N; Lu K; Yang X; Zhong B; Han Y; Zhang F; Li D; Lan X; Lu S
Mol Cell Endocrinol; 2022 Apr; 545():111562. PubMed ID: 35051553
[TBL] [Abstract][Full Text] [Related]
15. miR-222 targets ACOX1, promotes triglyceride accumulation in hepatocytes.
Wang JJ; Zhang YT; Tseng YJ; Zhang J
Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):360-365. PubMed ID: 31126802
[TBL] [Abstract][Full Text] [Related]
16. Hepatic
Lee YH; Jang HJ; Kim S; Choi SS; Khim KW; Eom HJ; Hyun J; Shin KJ; Chae YC; Kim H; Park J; Park NH; Woo CY; Hong CH; Koh EH; Nam D; Choi JH
Elife; 2021 Dec; 10():. PubMed ID: 34964438
[TBL] [Abstract][Full Text] [Related]
17. PPARα is one of the key targets for dendrobine to improve hepatic steatosis in NAFLD.
Xu Y; Wang M; Luo Y; Liu H; Ling H; He Y; Lu Y
J Ethnopharmacol; 2024 Apr; 323():117684. PubMed ID: 38171466
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-376b-3p ameliorates nonalcoholic fatty liver disease by targeting FGFR1 and regulating lipid oxidation in hepatocytes.
Wang XY; Lu LJ; Li YM; Xu CF
Life Sci; 2022 Nov; 308():120925. PubMed ID: 36057399
[TBL] [Abstract][Full Text] [Related]
19. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD.
Zheng L; Lv GC; Sheng J; Yang YD
J Gastroenterol Hepatol; 2010 Jan; 25(1):156-63. PubMed ID: 19780876
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
Nie H; Song C; Wang D; Cui S; Ren T; Cao Z; Liu Q; Chen Z; Chen X; Zhou Y
Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3087-3094. PubMed ID: 28951211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
